MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which
selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.
性状
Solid
IC50 & Target[1][2]
MMP-9
体外研究(In Vitro)
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Cytotoxicity Assay
体内研究(In Vivo)
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88.[2]. Alford VM, Kamath A, Ren X, et al. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-2803.
溶解度数据
In Vitro: DMSO : 66.67 mg/mL (180.49 mM; Need ultrasonic)配制储备液